



18 February 2026

Sydney, Australia

## Capital Structure Update

---

**Nyrada Inc (ASX:NYR)**, a clinical-stage biotechnology company developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions provides an update on its capital structure as at 12 February 2026 in the attached appendix.

– ENDs –



## Appendix 1

Class	Number of securities	Exercise price	Expiry
<b>CDIS</b>			
NYR : CHESS DEPOSITORY INTERESTS 1:1 US PROHIBITED	244,949,705	N/A	N/A
Sub Total	244,949,705		
<b>VESTED OPTIONS</b>			
NYRAI OPT4 : OPTION	2,900,000	\$0.40	29-Jun-26
NYRAI OPT5 : OPTION	2,000,000	\$0.60	29-Jun-26
NYRAI OPT6 : OPTION	2,000,000	\$0.90	29-Jun-26
NYRAI NYROPT3: OPTION	600,000	\$0.40	18-Jan-27
NYRAJ : OPTION	3,333,332	\$0.135	30-Jun-27
NYRAR : OPTION	6,944,000	\$0.45	22-Aug-27
NYRAK : OPTION	2,300,000	\$0.20	31-Dec-27
NYRAI NYRE: OPTION	450,000	\$0.20	17-Mar-28
NYRAI NYRE: OPTION	150,000	\$0.315	17-Mar-28
NYRAI NYROPT9: OPTION	600,000	\$0.9561	12-Nov-28
Sub Total	21,277,332		
<b>UNVESTED OPTIONS</b>			
NYRAI OPTION	14,000,000	TBC	25-Nov-2029
NYRAI OPTION	1,500,000	TBC	TBC
NYRAI OPTION <sup>1</sup>	600,000	TBC	12-Nov-2030
	600,000	TBC	12-Nov-2031
NYRAI OPTION <sup>1</sup>	3,000,000	\$0.7968	12-Nov-2029
	3,000,000	\$0.7968	12-Nov-2030
	3,000,000	\$0.7968	12-Nov-2031
NYRAO : OPTION	1,781,250	\$0.19	11-Jun-2031
NYRAP : OPTION	1,781,250	\$0.19	11-Jun-2032
NYRAQ : OPTION	2,137,500	\$0.19	30-Jun-2033
Sub Total	31,400,000		

<sup>1</sup> Approved by CDI holders at 2025 Annual General Meeting, as at date of announcement, options have not yet been issued and accepted.



## About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in both cardioprotection and neuroprotection, and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial is soon to commence. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by John Moore, Non-Executive Chair, on behalf of the Board.*

### **Investor & Media Enquiries:**

Dimitri Burshtein  
T: 0491 789 391  
E: [info@nyrada.com](mailto:info@nyrada.com)

### **Company Secretary:**

David Franks  
T: 02 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### **Forward-Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.